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Background: D-bifunctional protein (DBP) deficiency is typically apparent within the first month of life with most
infants demonstrating hypotonia, psychomotor delay and seizures. Few children survive beyond two years of age.
Among patients with prolonged survival all demonstrate severe gross motor delay, absent language development,
and severe hearing and visual impairment. DBP contains three catalytically active domains; an N-terminal
dehydrogenase, a central hydratase and a C-terminal sterol carrier protein-2-like domain. Three subtypes of the
disease are identified based upon the domain affected; DBP type I results from a combined deficiency of
dehydrogenase and hydratase activity; DBP type II from isolated hydratase deficiency and DBP type III from isolated
dehydrogenase deficiency. Here we report two brothers (16½ and 14 years old) with DBP deficiency characterized
by normal early childhood followed by sensorineural hearing loss, progressive cerebellar and sensory ataxia and
subclinical retinitis pigmentosa.
Methods and results: Biochemical analysis revealed normal levels of plasma VLCFA, phytanic acid and pristanic
acid, and normal bile acids in urine; based on these results no diagnosis was made. Exome analysis was
performed using the Agilent SureSelect 50Mb All Exon Kit and the Illumina HiSeq 2000 next-generation-sequencing
(NGS) platform. Compound heterozygous mutations were identified by exome sequencing and confirmed by
Sanger sequencing within the dehydrogenase domain (c.101C>T; p.Ala34Val) and hydratase domain (c.1547T>C;
p.Ile516Thr) of the 17β-hydroxysteroid dehydrogenase type 4 gene (HSD17B4). These mutations have been
previously reported in patients with severe-forms of DBP deficiency, however each mutation was reported in
combination with another mutation affecting the same domain. Subsequent studies in fibroblasts revealed normal
VLCFA levels, normal C26:0 but reduced pristanic acid beta-oxidation activity. Both DBP hydratase and
dehydrogenase activity were markedly decreased but detectable.
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Conclusions: We propose that the DBP phenotype seen in this family represents a distinct and novel subtype of
DBP deficiency, which we have termed type IV based on the presence of a missense mutation in each of the
domains of DBP resulting in markedly reduced but detectable hydratase and dehydrogenase activity of DBP. Given
that the biochemical testing in plasma was normal in these patients, this is likely an underdiagnosed form of DBP
deficiency.
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D-bifunctional protein (DBP) deficiency is an autosomal
recessive disorder of peroxisomal fatty acid oxidation.
The term bifunctional originated from the discovery that
this single enzyme contained multiple active domains re-
sponsible for sequential steps in peroxisomal β-oxidation.
Specifically, DBP catalyzes the second step (hydration)
and third step (dehydrogenation) of β-oxidation of the
very long chain fatty acids (VLCFA) C26:0, branched-
chain fatty acids (pristanic acid) [1] and bile acid
intermediates (dihydroxycholestanoic acid (DHCA) and
trihydroxycholestanoic acids (THCA)) [2]. DBP contains
three domains and is encoded by the 17-β hydroxy-
steroid dehydrogenase type 4 (HSD17B4) gene. The
N-terminal short-chain alcohol dehydrogenase domain
is encoded by exons 1–12, the central 2-enoyl-CoA
hydratase domain is encoded by exons 12–21 and the
C-terminal sterol carrier protein 2-like domain (SCP-2L)
is encoded by exons 21–24 [3]. DBP is a homodimeric
enzyme with 79 kD subunits. After import into the
peroxisome, the protein is cleaved resulting in a 35 kD
dehydrogenase unit and a 45 kD hydratase plus SCP-2L unit.
DBP deficiency is classified into three subtypes
depending upon the deficient activity. DBP deficiency
type I is a deficiency of both 2-enyol-CoA hydratase and
3-hydroxyacyl-CoA dehydrogenase activity, DBP defi-
ciency type II is a deficiency of hydratase activity alone,
and DBP deficiency type III is a deficiency of the
dehydrogenase activity alone [3]. Recent clinical and bio-
chemical review of over 100 patients with DBP defi-
ciency has documented a similar clinical phenotype
among patients with all three biochemical subtypes [4,5].
Virtually all patients present within the first month of
life with hypotonia and seizures with over two-thirds
also demonstrating Zellweger-like facial features (i.e.
high forehead, high arched palate, enlarged fontanelle,
long philtrum, hypertelorism) [4]. Most infants (>80%)
with DBP deficiency die before 2 years old, typically of
respiratory complications [4]. Biochemical testing typic-
ally identifies elevated levels of plasma C26:0, DHCA,
THCA as well as pristanic acid and its precursor phyta-
nic acid [6]. Only a small minority (<2%) of DBP defi-
cient patients will show normal biochemical testing
[4,7,8]. This stresses the importance of studies incultured skin fibroblasts in such circumstances where
there is clinical suspicion of a disorder of peroxisome
function.
We report two brothers with confirmed DBP defi-
ciency. While the boys demonstrated some of the typical
clinical features of peroxisome dysfunction (hearing
impairment, cerebellar and sensory ataxia) they showed
no demonstrable biochemical abnormality of plasma
VLCFA, pristanic acid and phytanic acid or urinary bile
acids. Exome sequencing was essential for detecting
compound heterozygous mutations in both DBP hydra-
tase and dehydrogenase domains Further fibroblast en-
zyme testing for DBP activity confirmed markedly
reduced but detectable hydratase and dehydrogenase ac-
tivity. We propose that our patients have a novel form of
DPB deficiency, which we have designated type IV on
the basis of their unique clinical, biochemical and gen-
etic features, thereby expanding the phenotypic
spectrum associated with alteration of DBP function.
Patients and methods
Institutional research ethics board approval (Children’s
Hospital of Eastern Ontario) was obtained prior to exome
sequencing. Each family member provided informed con-
sent for exome sequencing as well as permission to pub-
lish clinical information and images contained within
this report.
Patient 1
A 16½-year-old boy was identified with expressive lan-
guage delay and articulation difficulty at 3½ years old,
resulting from a moderate-to-severe sensorineural hear-
ing impairment. His language development completely
normalized with hearing aids. His early gross and fine
motor development was normal; he was able to skate
and play hockey as a child. He did well academically
within a regular classroom setting. At 11 years old, he
developed insidious, progressive gait ataxia. He was
found to have bilateral pes cavus and mild hammertoe
foot deformity, diffuse areflexia and flexor plantar
responses. Very mild weakness of anterior compartment
muscles was noted prompting prescription of ankle-
foot orthoses. Small fiber sensory testing was slightly
decreased in a stocking distribution. Vibration sense
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tion was apparent; rapid finger movements were slow
and heel-to-shin testing was impaired. Romberg sign was
negative. Nerve conduction studies (Table 1) revealed a
mild sensorimotor polyneuropathy with demyelinating
features (motor conduction velocities; 20–25 m/sec; nor-
mal upper-extremity is ≥50 m/sec and lower extremity
≥40 m/sec). Sensory and motor nerve amplitudes were
normal except for low common peroneal nerve CMAP
amplitude. Over time, his pes cavus worsened and his





DML (wrist to APB) < 4.2
CMAP (mV) ≥ 3.9
CV (m/sec) > 47
Ulnar nerve
DML (msec; wrist to ADM) < 3.4 2.6
CMAP (mV) ≥ 5.9 13.1
CV (m/sec) > 47 25
Tibial nerve
DML (msec; ankle to AH) < 6.0 5.3
CMAP (mV) ≥ 3.9 3.3
CV (m/sec) > 39 21
Peroneal nerve
DML (msec; ankle to EDB) < 6.0 5.0
CMAP (mV) ≥ 2.4 1.7
CV (m/sec) > 39 22
SENSORY:
Median nerve
PL (msec; wrist to digit-II) < 3.2 2.5
SNAP (μV) ≥ 14 67
CV (m/sec) 46
Ulnar nerve
PL (msec; wrist to digit-V) < 3.3 2.0
SNAP (μV) ≥ 9 43
CV (m/sec) 47
Sural nerve
PL (msec; calf to lat mall) < 4.2 3.8
SNAP (μV) ≥ 5 11
CV (m/sec) 42
Bold and underlined values are abnormal. All sensory responses are antidromic.
Legend: DML=distal onset motor latency; CMAP=compound motor action potential
ADM=abductor digiti minimi; AH=abductor hallucis; EDB=extensor digitorum brevisdemyelination (increasing latency prolongation) and
length-dependent axonal loss (progressive loss of motor
and sensory amplitudes). Fundoscopic examination at
15½ years old revealed widespread peripheral retinal at-
rophy with sparing of the central macula (i.e. severe rod
dysfunction with relative sparing of cones) consistent
with retinitis pigmentosa (Figure 1). Visual acuity was
normal. Visual evoked potentials were normal. Scotopic
rod electroretinograms (ERG) revealed mild abnormality,
indicating rod dysfunction in the peripheral retina. Pho-
topic cone and 30 Hz flicker were also abnormalPatient 1 Patient 2
Age at study






















; CV=conduction velocity; PL=peak onset latency; APB=abductor pollicus brevis;
; NR=no response.
Figure 1 Retinal photograph of Patient 1 at 15½ years old identified retinitis pigmentosa. Widespread peripheral retinal atrophy was seen
with relative sparing of the central macula. Clinically this corresponds to involvement of peripheral rods and relative sparing of cones.
Figure 2 MRI of the brain. MRI was performed on Patient 1 at 12
years of age. T1W1 sagittal image demonstrates prominent
cerebellar atrophy involving superior and middle cerebellar folia.
Axial images (not shown) revealed normal subcortical and cerebellar
white matter. MR spectroscopy was normal (not shown). Repeat MRI
imaging at 16 years old was unchanged (not shown). MRI of the
brain (Patient 2) showed a similar pattern but milder cerebellar
atrophy (not shown).
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at 16½ years old he remained ambulatory for short dis-
tances at home but due to his significant ataxia, a wheel-
chair is required for longer distances. He showed no
evidence of growth or pubertal delay. His height has fol-
lowed the 10-25th %ile and at 16-years old he was noted
to have age-appropriate pubertal development; Tanner
IV pubic hair and 12–15 mL testicular volume. His cog-
nition, language and vision remain intact. He has no clin-
ical or biochemical evidence of renal or hepatic
involvement.
MRI of the brain at 12 years of age revealed cerebellar
atrophy (Figure 2). Extensive genetic and metabolic test-
ing was performed over a span of several years, includ-
ing normal PMP22 duplication / deletion analysis, MPZ,
GJB1, PMP22 and c10orf2 gene sequencing, spinocere-
bellar ataxia panel (SCA 1,2,3,6,7,8,17), Friedreich ataxia
expansion testing and serum vitamin E level. Chromo-
some microarray was normal. Muscle biopsy (at 15-years
old) revealed mild neurogenic changes. Muscle respira-
tory chain enzyme testing was normal. He was con-
firmed to have normal levels of plasma adrenal and
testicular sex steroids.
Family history was remarkable for his younger brother
with similar features; his parents, older sister and
extended family members were all unaffected. His par-
ents were not consanguineous, and were of German and
Irish descent.
Patient 2
The 14-year-old younger brother was identified at 2-years
of age with moderate-to-severe sensorineural hearing loss
requiring hearing aids. His early neurodevelopment was
normal. He remains quite physically active; and at last
follow-up was able to ice-skate 3 km and cross-country
ski for 1-1½ hours. He does not require ankle-foot
orthoses or any other assistive devices. His exam wassignificant for very mild pes cavus and hyporeflexia
(biceps 1+, brachioradialis 1+, triceps 2+, patella 1+,
ankle jerk 0), flexor plantar responses and mild anterior
compartment weakness (tibialis anterior 4+/5, peroneus
longus 4+, extensor hallucis longus 4). Sensory testing
was normal except for pin-prick hyperesthesia to his
toes. Mild ankle tightness was noted. Coordination was
normal. Nerve conduction studies (Table 1) revealed a
mild sensorimotor polyneuropathy with demyelinating
features. Fundoscopic examination revealed widespread
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macula. Visual acuity and ERG were normal. His cogni-
tion is intact and he achieves good academic grades
within a regular classroom setting. He has demonstrated
a normal growth velocity although his height has
remained just below the 5th %ile. At almost 14 years old,
he shows no sign of pubarche with Tanner I pubic hair
and 5 mL testicular volume. At a chronological age of 13
years 8 months his bone age was 11 years old, consistent
with constitutional delay of growth and puberty. He
shows no evidence of renal or hepatic involvement.
Exome sequencing
Exome capture and high-throughput sequencing of
DNA from the two brothers was performed at McGill
University and Genome Québec Innovation Centre
(Montréal, Canada). Total genomic DNA was extracted
from blood following standard procedures. Exome target
enrichment was performed using the Agilent SureSelect
50Mb All Exon Kit, and sequencing (Illumina HiSeq)
generated 65 Gbp of 100 bp paired-end reads per sam-
ple. Mean coverage of coding sequence regions (CCDS),
after accounting for duplicate reads was 237x and 212x
for each of the affected brothers. 91.5% of CCDS bases
in Patient 1 and 90.0% of CCDS bases in Patient 2 had
≥20x coverage and ≥5x coverage was seen in 96.8% of
CCDS bases in both siblings. An in-house annotation
pipeline was used to call and annotate coding and
splice-site variants. Reads were trimmed and sequences
with a matching (opposite) read were aligned to hg19
using BWA [9]. Duplicate reads were marked using Pic-
ard [10] and excluded. Single nucleotide variants and
short insertions and deletions (indels) were called using
SAMtools pileup [11] and varFilter and quality-filtered
to require a minimum 20% of reads supporting the vari-
ant call. Variants were annotated using Annovar [12] as
well as custom scripts to select coding and splice-site
variants, and to exclude common (≥1% minor allele fre-
quency) polymorphisms represented in the NHLBI
exome server [13], or in 435 control exomes sequenced
at our center. Variants were prioritized based on those
identified in both affected patients. Given the presumed
autosomal recessive mode of inheritance, only genes
with homozygous or multiple heterozygous variants
were considered.
Variant validation
Sanger sequencing was used to validate mutations iden-
tified by next-generation sequencing and to evaluate seg-
regation of variants in the family. Blood samples were
obtained and DNA was extracted from the affected
brothers and unaffected parents and sister. PCR was
performed with primers 50-GAGTGGATAGGTTGAG
AATGTCAGTG-30 and 50-TTTAGACAGACAGCCTTAGTCGGG-30 to test for the c.101C>T variant and
50-ACCAATAACCAGCCATGTTTCCT-30 and 50-TCC
TACCTTTCCATATCCTTTGCAT-30 to test for c.1547T>C
variant.
Biochemical analysis
Biochemical testing in fibroblasts was performed as
described [4] (Table 2).
Results
Exome sequencing and variant validation
Two variants, c.1547T>C (p.Ile516Thr) at chr5:118860954
and c.101C>T (p.Ala34Val) at chr5:118792052 were iden-
tified in HSD17B4 (Table 3). c.1547T>C was found in a
region of very low coverage, present in only 2 of 8 reads
(variant quality of 18.4%) in Patient 2 and therefore was
only identified by visual inspection once the two variants
had been annotated in his brother. Sanger sequencing
confirmed c.1547T>C and c.101C>T in both brothers.
Parents were each heterozygous for one of the muta-
tions; c.1547T>C; p.Ile516Thr inherited from the
mother and c.101C>T; p.Ala34Val inherited from the
father (Figure 3). Both mutations were predicted to be
deleterious by the SIFT algorithm [14] (SIFT score 0.03
and 0 respectively) and probably damaging by PolyPhen2
[15] (HumDiv score 0.999 and 0.997 respectively). Both
mutations have been reported separately to be disease-
causing [5]; however, they have not been seen in combin-
ation before.
Biochemical analyses
Plasma levels of VLCFA and branched chain fatty acids
(pristanic acid and phytanic acid) were normal (Kennedy
Krieger Institute, Baltimore, USA; Table 2). Plasma doc-
osohexanoic acid (DHA) levels were also normal (data
not shown, Kennedy Krieger Institute, Baltimore, USA).
Urine was analyzed using fast atom bombardment
ionization mass spectrometry with no abnormalities
identified in urine bile acid secretion (data not shown,
Cincinnati Children’s Hospital Medical Center, USA).
Fibroblast studies at the Laboratory of Genetic Meta-
bolic Diseases (Academic Medical Center, Amsterdam,
The Netherlands) revealed normal VLCFA levels and
normal C26:0 beta-oxidation, but reduced pristanic acid
beta-oxidation activity (Table 2). Catalase immunofluor-
escence studies showed normal to near-normal peroxi-
somal staining with respect to number and morphology
of peroxisomes (Table 2). Peroxisomes were slightly
increased in size in Patient 1. DBP enzyme activity mea-
surements revealed reduced hydratase and dehydrogen-
ase activities (Table 2). The amount of DBP protein was
reduced on immunoblot (Table 2 and data not shown,
Laboratory of Genetic Metabolic Diseases, Academic
Medical Center, Amsterdam, The Netherlands).
Table 2 Patient plasma and fibroblast biochemical analyses
Test Units Patient 1 Patient 2 Reference range
Plasma:
VLCFA concentration
C26:0 Hexacosanoic μg/mL 0.220 0.270 0.23 ± 0.09*
C26/C22 0.021 0.012 0.01 ± 0.004*
C24/C22 0.918 0.967 0.84 ± 0.918*
Phytanic acid μg/mL 1.260 0.810 < 3.0
Pristanic acid μg/mL 0.140 0.060 < 0.3
Fibroblasts:
Catalase immunofluorescence Near-normal Normal Normal
VLCFA concentration:
C26:0 concentration μmol / g protein 0.20 0.20 0.18 - 0.38
C24:0 concentration μmol / g protein 6.52 6.79 7.76 - 17.66
C22:0 concentration μmol / g protein 3.00 3.23 3.84 - 10.20
Ratio C26:0 / C 22:0 0.07 0.06 0.03 - 0.07
Ratio C24:0 / C 22:0 2.18 2.10 1.55 - 2.30
Peroxisome function:
β-oxidation (of C16:0) pmol / (mg protein / hour) 3876 5061 3330 - 7790
β-oxidation (of C26:0) pmol / (mg protein / hour) 1290 1325 800 - 2040
β-oxidation (of pristanic acid) pmol / (mg protein / hour) 157 248 790 - 1690
α-oxidation (of phytanic acid) pmol / (mg protein / hour) 38 45 28 - 95
D-bifunctional protein activity:
Hydratase pmol / (mg protein / min) 43 53 115 - 600
Dehydrogenase pmol / (mg protein / min) 2 3 25 - 300
Immunoblotting:
DBP 79 kDa Trace Trace Present
DBP 45 kDa Absent Absent Present
DBP 35 kDa ±/− ±/− Present
Plasma testing was performed at Kennedy-Krieger Institute (Baltimore, USA). Fibroblast testing was performed at the Laboratory Genetic Metabolic Diseases
(Amsterdam, The Netherlands).
Bold and underlined values are abnormal; *Indicates mean +/− 1 standard deviation.
Table 3 Filtering of exome sequencing variants
Genes with missense, nonsense, indel or splice variants 6453
Genes with rare mutations1 372
Genes with mutations shared by siblings 109
Genes with homozygous/ multiple heterozygous mutations 22
1Variants were filtered out if they had a minor allele frequency (MAF) >0.01 in
the 1000 genomes database, the NHLBI exome server or were seen in >2 of
435 control exomes sequenced at our center.
2The 2 genes were C16orf82 and FAM83C; these genes were rejected as
candidates since two control samples possessed identical sequence variants in
C16orf82 and one control sample possessed an identical sequence variant in
FAM83C. The 109 genes with at least one mutation shared by the siblings
were then re-examined and the HSD17B4 mutations were identified. The
second HSD17B4 mutation was not initially identified in Patient 2 due to low
coverage (given presence in only 2/8 reads it was given a variant quality of
18.4 which is below our threshold of 20).
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Our exome sequencing of two siblings with a previously
undiagnosed neurodegenerative disorder has detected
compound heterozygous mutations c.101C>T (p.Ala34Val)
and c.1547T>C (p.Ile516Thr) in HSD17B4 affecting the
dehydrogenase and hydratase domains, respectively. Both
missense mutations have been previously reported, but
in both cases with a second missense mutation affecting
the identical DBP domain on the other allele [5]. The
first case was compound heterozygous for p.Ala34Val
and p.Phe237Ser; both mutations affecting the dehydro-
genase domain resulting in DBP type III and an isolated
dehydrogenase deficiency. The second case was com-
pound heterozygous for p.Ile516Thr and p.Asn457Tyr; in
this instance both mutations occur within the hydratase
domain causing DBP type II and an isolated hydratase
deficiency. Although this patient with DBP type II
R          G         A/V         L           V
*








Patient 1 Patient 2
N  X N  X






Figure 3 Sanger sequencing and segregation. (A) Pedigree of family with DBP deficiency. X=variant; N=normal. (B) Sanger sequencing
validation of HSD17B4 variants identified by exome sequencing. Genomic DNA was amplified for sequencing with primers flanking exon 2 and 18
(see text for primer sequences). Asterisks indicate heterozygous mutations. Red X = c.101C>T (p. Ala34Val) at chr5:118792052. Blue X = c.1547T>C
(p. Ile516Thr) at chr5:118860954.
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were significant.
An obvious explanation for the relatively milder clin-
ical phenotype observed in our patients is the fact
that only one domain on each allele is affected with a
less severe mutation. The attenuated clinical phenotype
and biochemical testing indicates normal transcription,
translation, and the normal import of the DBP enzyme
into an intact and functional peroxisome. The latter
is supported by normal catalase immunoflorescence
observed in our patients indicating normal peroxisome
biogenesis and morphology; a finding not seen in
patients with the more severe form of DBP deficiency
[4]. Little information is available on the impact of the
p.Ala34Val mutation and analysis demonstrated low
residual enzyme activity of the dehydrogenase domain.
The p.Ile516Thr is located at the dimerization inter-
face of the hydratase subunits but does not abolish
dimerization completely, implying residual activity [5].
The apparent discrepancy between the residual hydra-
tase activity (~40% of lower limit of normal) and ab-
sence of the hydratase domain on immunoblot may in
part be accounted for by the fact that L-Bifunctional
protein (L-BP) is responsible for part of the measured
hydratase activity because it can metabolize the sub-
strate THC:1-CoA to the (24S,25S)-isomer of 24OH-
THC-CoA which cannot be metabolized further by the
dehydrogenase domain of L-BP. The result could also,
in part, represent a combination of altered structure
and stability of the mutant DBP enzyme. Finally, both
sets of homodimers (hydratase and dehydrogenase
domains) likely have some physical and functional rela-
tionship to each other. A mutation in one domain has
the potential to alter function and stability of the otherunit even if a mutated domain (e.g. dehydrogenase)
forms a dimer with an adjacent wild-type domain (e.g.
hydratase). As such, the in vivo function of this enzyme
appears more complicated than that predicted by
in vitro studies.
Although some other peroxisome diseases resulting
from single enzyme defects can present in adulthood (i.e.
acyl-CoA oxidase (ACOX) deficiency [16] and sterol car-
rier protein X (SCPx) deficiency [17]), this has not been
reported for DBP deficiency [4]. Since both hydratase
and dehydrogenase activities are affected, our patients
would be deemed to be type I under the current DBP de-
ficiency classification. However, the significant majority
of type I-deficient patients have mutations in HSD17B4
encoding truncated or unstable proteins resulting in a
severe phenotype and poor survival [4]. In our estima-
tion, the mild clinical and biochemical phenotype in
our patients warrant a new classification. We therefore
propose a novel variant of DBP deficiency, designated
DBP type IV, due to compound heterozygous mutations
affecting two different domains of DBP but associated with
a relatively milder clinical and biochemical phenotype.
Our newly proposed subtype of DBP deficiency (type IV)
would also apply to two sisters recently diagnosed
with Perrault syndrome caused by compound hetero-
zygous mutations within HSD17B4, one affecting the
dehydrogenase domain and one the hydratase domain,
similar to our patients. In this instance, the sisters’ rela-
tively milder phenotype was characterized by sensori-
neural deafness, mild intellectual disability, sensorimotor
polyneuropathy, short stature and ovarian dysgenesis [7].
Exome sequencing was also essential in obtaining this
diagnosis but complete biochemical testing including
DBP enzyme activity measurement was not reported.
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intelligence and pubertal development (in the older
brother).
The overall incidence of peroxisomal disorders is ap-
proximately 1 in 5,000 newborns [6], most of these cases
are severe and are thus readily ascertained. In striking
contrast to previously reported patients [4,5], the two
brothers described here did not demonstrate any neo-
natal or infantile symptoms, moreover they continue
to demonstrate normal cognition. Their slow clinical
course of DBP deficiency has allowed, for the first
time, serial electrodiagnostic testing in DBP patients; the
clinical exams and nerve conduction studies spanning
several years (Table 1) document a gradual decline of
coordination reflecting increasing cerebellar and sensory
nerve dysfunction. The progressive sensorimotor poly-
neuropathy demonstrated uniform conduction velocity
slowing, reminiscent of that seen with many hereditary
demyelinating polyneuropathies (e.g. Charcot-Marie-
Tooth, type 1). The older sibling (Patient 1) not only
demonstrated progressive demyelination (increasing la-
tencies and conduction velocity slowing) but also evi-
dence of progressive, length-dependent axonal loss. The
introduction of readily available exome sequencing into
rare disease clinics will lead to the recognition of add-
itional patients with milder variants of DBP deficiency
and will improve our understanding of the phenotypic
spectrum and natural history of this and other diseases.
Conclusion
We propose that the DBP phenotype seen in this family
represents a distinct and novel subtype of DBP defi-
ciency, which we have termed type IV based on the
presence of a missense mutation in each of the domains
of DBP, reduced but detectable hydratase and dehydro-
genase activities and relatively milder clinical and bio-
chemical features. Without exome sequencing, the
diagnosis of DBP deficiency may not have been made in
our patients given their normal biochemical testing in
plasma and urine. These patients highlight the import-
ance of exome sequencing as a diagnostic tool, particu-
larly in phenotypically and genotypically heterogeneous
disorders or in cases with atypical clinical presentations.
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